SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of people being let go with hand showing them to door
Layoffs
Genentech’s Latest Layoffs Bring Total to Nearly 350 This Year
Genentech is letting go of 118 employees in South San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.
October 29, 2025
 · 
1 min read
 · 
Angela Gabriel
Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.
Earnings
GSK Points to ‘Macro Factors’ To Explain US Shingrix Demand Crash
Shingrix sales in the U.S. took a 15% dive in the third quarter. GSK is now the second Big Pharma to report declining vaccine sales, after Sanofi reported a similar decline last week.
October 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Building a rocket. Halftone hands assemble a rocket shaped puzzle. Concept of a startup, new business. Hasty rocket launch. Innovation, teamwork, development of ideas and technologies
Clinical research
BridgeBio Shares Pop Again as Phase III Thyroid Drug Exceeds Investor Expectations
Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a genetic thyroid disorder.
October 29, 2025
 · 
3 min read
 · 
Annalee Armstrong
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Earnings
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues
Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing troubles for the franchise.
October 29, 2025
 · 
2 min read
 · 
Tristan Manalac
The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.
Immunology and inflammation
Aldeyra Cans RASP Asset, Brings Forward Two Others in Pipeline Shakeup
The reprioritization initiative extends Aldeyra’s cash runway into the second half of 2027.
October 29, 2025
 · 
2 min read
 · 
Tristan Manalac
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
J&J, Lilly Crest AI Wave With Nvidia Partnerships
Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to create the industry’s ‘most powerful supercomputer’ and J&J building a virtual operating room.
October 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; Novartis’ CEO also downplayed the impact of Big Pharma pricing deals with the Trump administration; Regeneron continued the trend of dropping cell therapy assets; BioSpace takes a look at how the FDA is functioning mid-shutdown.
October 29, 2025
 · 
1 min read
 · 
Heather McKenzie
USA shutdown and United States government closed and american federal shut down due to spending bill disagreement between the left and the right pas a national finance symbol with yellow hazard tape in a 3D illustration style.
Government
FDA Struggles To Keep Lights On Amid Shutdown as Biopharmas Begin To See Delays
While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in dealings with the agency, while insiders warn of falling morale and a negative perception from the rest of the biopharma world.
October 29, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Big fish eat small fish, in a competitive business market who has more resources or having more bargaining power is a win. But we can overcome them by being different.
Mergers & acquisitions
5 SMID-Cap Pharmas Poised for M&A Action
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.
October 29, 2025
 · 
7 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS